



**NIH HEALTH CARE SYSTEMS RESEARCH COLLABORATORY**

# **STAKEHOLDER ENGAGEMENT CORE**

**SEAN TUNIS, MD, MSc**

**CENTER FOR MEDICAL TECHNOLOGY POLICY**

**MARCH 1, 2013**


## SE CORE WORKGROUP MEMBERS

<ul style="list-style-type: none"> <li>• Sally Retecki</li> </ul>	Strategies and Opportunities to Stop Colon Cancer in Priority Populations
<ul style="list-style-type: none"> <li>• Jerry Jarvik</li> <li>• Katie James</li> </ul>	A Pragmatic Trial of Lumbar Image Reporting with Epidemiology (LIRE)
<ul style="list-style-type: none"> <li>• Lynn DeBar</li> <li>• Carmit McCullen</li> </ul>	Collaborative Care for Chronic Pain in Primary Care
<ul style="list-style-type: none"> <li>• Mark Vander Weg</li> </ul>	Nighttime Dosing of Anti-Hypertensive Medications: A Pragmatic Clinical Trial
<ul style="list-style-type: none"> <li>• Alfred Cheung</li> </ul>	Pragmatic Trials in Maintenance Hemodialysis
<ul style="list-style-type: none"> <li>• Greg Simon</li> </ul>	Pragmatic trial of population-based programs to prevent suicide attempt
<ul style="list-style-type: none"> <li>• Susan Huang</li> <li>• Ed Septimus</li> </ul>	Decreasing Bioburden to Reduce Healthcare-Associated Infections and Readmissions
<ul style="list-style-type: none"> <li>• Sean Tunis</li> <li>• Rachael Moloney</li> <li>• Ellen Tambor</li> </ul>	CMTP / SE Core Staff
<ul style="list-style-type: none"> <li>• Tammy Reece</li> </ul>	Duke Coordinating Center
<ul style="list-style-type: none"> <li>• Russ Glasgow</li> <li>• David Chambers</li> </ul>	NIH Representatives to the SE Core

# OVERVIEW

- What are stakeholders?
- What is stakeholder engagement?
- Why engage stakeholders in CER?
- Why engage stakeholders in the Collaboratory?
- SE Core progress to date
  - Identification of high priority issues
  - SAG recruitment
- Discussion

## Stakeholder Categories



# STAKEHOLDER ENGAGEMENT

- A process of actively soliciting the knowledge, experience, judgment and values of individuals selected to represent a broad range of direct interests in a particular issue, for the dual purposes of:


*1) Creating a shared understanding;*

*2) Making relevant, transparent, and effective decisions.*

# WHY ENGAGE STAKEHOLDERS IN CER

- Gaps in evidence will be reduced with greater collaboration between decision makers, researchers and other stakeholders in:
  - Priority setting
  - Defining research questions
  - Designing and reviewing study protocols
  - Implementing studies
  - *Disseminating / implementing results*

# CONCEPTUAL MODEL



# **WHY ENGAGE STAKEHOLDERS IN THE COLLABORATORY?**

(other than it being the fashionable  
thing to do)



# COLLABORATORY GOALS

- “...to strengthen the national capacity to implement cost-effective large-scale research studies that engage health care delivery organizations as research partners.”
- “...to provide a framework of implementation methods and best practices that will enable the participation of many health care systems in clinical research.”

# FROM VISION TO REALITY

- Many barriers to metamorphosis from health care delivery system to research partner
- Health systems and research community don't have all necessary authority, resources, insights
  - Optimal “implementation methods and best practices” may require actions by other agents
- Stakeholder Engagement Core provides forum to engage broader healthcare community
  - Shared understanding and decisions / actions

## STATEMENT OF PURPOSE

- The **Stakeholder Engagement (SE) Core** will provide the forum within which a broad range of stakeholders can discuss how best to deploy their authorities, resources and insights to support the Collaboratory goal of transforming healthcare delivery organizations into research partners.
- The dialogue will also require us to clarify why this transformation is important for these organizations, their employees and the patients they serve.


## SE CORE WORK TO DATE

- Develop initial statement of purpose
  - Feedback from Collaboratory Steering Committee
- Identify potential issues for Stakeholder Advisory Group (SAG)
- Identify and recruit SAG members, based on issues and stakeholder categories
  - 16 confirmed; target size 20-25
  - Scheduled first in person mtg of SAG on May 9
- Discussion with broader Collaboratory community (today)

## IDENTIFYING TOPICS FOR SAG DISCUSSION

- Conducted interviews with representatives from each of the 7 demonstration projects to:
  - Identify generalizable challenges best addressed at a higher level, in a broad stakeholder discussion
  - Elicit suggestions for stakeholder groups or organizations relevant to challenges/issues
- Developed preliminary list of discussion topics
- Feedback from Collaboratory Steering Group and Stakeholder Engagement workgroup

# SUGGESTED TOPICS FOR SAG



# Informed Consent and IRB Review

1. Barriers related to informed consent in healthcare systems research
  - a) Individual consent in cluster RCTs and other PCTs
  - b) Consent for use of clinical and administrative data generated through routine clinical care
  - c) Differences in and potential standardization of “minimal risk” definitions
2. Mechanisms to encourage greater reliance on central IRBs

# Reimbursement

1. Payment for routine clinical services that are being evaluated in the trial
  - a. “Investigational” vs. “experimental” confusion
2. Implications of Medicare clinical trials policy
3. Coverage for new interventions that are a combination of existing covered services
4. Willingness of delivery system or payers to support innovative care delivery models after positive trial results



# CLINICIAN AND PATIENT INCENTIVES

- For some demo projects, participation in research is low priority for clinicians
- Patient recruitment challenges also noted
- Potential role for “behavioral economics”
- Existing payment rules, quality reporting requirements can be disincentive to participate

## OTHER POTENTIAL ISSUES

- Competition for attention to research during ACA-driven delivery and payment reform
- How to most efficiently align HCS research with other data-intensive activities
  - Quality improvement programs, quality measurement and reporting, clinical registries...
- How and when best to plan for practice and policy changes indicated by study results

# CRITERIA FOR SAG MEMBERS

- Organizations and individuals who are likely to have authorities, resources, insights related to one or more of the key issues
- Special emphasis on those not already engaged in healthcare systems research
- Broad range of relevant professional experience



# STAKEHOLDER ADVISORY GROUP (SAG): CONFIRMED MEMBERS

## Patients/Consumers/Advocates

***Marc Boutin, JD***

Executive VP & Chief Operating Officer  
National Health Council

***Pam Wescott, MPP***

Director of Patient Perspectives  
Informed Medical Decisions Foundation

***Donna Cryer, JD (liver patient)***

Chief Executive Officer  
Cryer Health

***Deborah Collyar (cancer survivor)***

Co-Chair, Committee on Advocacy,  
Research Communications, Ethics, &  
Underserved Populations  
National Breast Cancer Coalition

## Regulatory/Ethics

***Susan Kornetsky, MPH***

Director of Clinical Research Compliance  
Children's Hospital, Boston

***Alex Capron, LLB***

Chair, Board of Directors  
Public Responsibility in Medicine and  
Research (PRIM&R)

## Clinical care providers

***Lyle Fagnan, MD***

Professor, Family Medicine  
Oregon Rural Practice-based Research Network  
Oregon Health & Science University

***Robert Chow, MD, MBA, FACP***

Program Director, Internal Medicine Residency  
Training Program and Vice-Chair of Medicine,  
Good Samaritan Hospital of Maryland

## SAG MEMBERS (CONT'D)

### Thought leaders in QI, practice incentives, and innovative care delivery

***Scott Halpern, MD, PhD, MBE***

Deputy Director  
Center for Health Incentives and Behavioral Economics  
Penn Leonard Davis Institute

***Peggy O'Kane, MHA***

President  
National Committee for Quality Assurance

***Kavita Patel, MD, MS***

Managing Director for Clinical Transformation and Delivery, Engelberg Center for Health Care Reform, Brookings Institution

### Public payers

***Patrick Conway, MD, MSc***

Director and CMS Chief Medical Officer  
Office of Clinical Standards and Quality

***Jeff Schiff, MD, MBA***

Medical Director  
Minnesota Healthcare Programs

### Private payers

***Derek van Amerongen, MD, MS***

Chief Medical Officer  
Humana of Ohio

***Elizabeth Malko, MD, MEng, FAAFP***

Executive VP and Chief Medical Officer  
Fallon Community Health Plan

# SAG MEMBERS (CONT'D)

## Patient Centered Outcomes Research Institute (PCORI)

***Rachael Fleurence, PhD***

Acting Director, Accelerating PCOR Methods  
Program, PCORI

## Healthcare System Administrators

**TBD, (Recruiting)**

## Health IT

***Kelly Cronin***

Healthcare Reform Coordinator  
Office of the National Coordinator for HIT

## Life Sciences Industry

***TBD (Recruiting)***

# MAXIMIZING VALUE OF SAG

- Demonstration projects, other workgroups are “living laboratories” to identify critical topics for SAG attention
- Active input and direction from Collaboratory participants essential to focusing SAG attention on most critical issues

# QUESTIONS / SUGGESTIONS